CA2829773A1 - Systems, devices and methods for assembling automatic injection devices and sub-assemblies thereof - Google Patents
Systems, devices and methods for assembling automatic injection devices and sub-assemblies thereof Download PDFInfo
- Publication number
- CA2829773A1 CA2829773A1 CA2829773A CA2829773A CA2829773A1 CA 2829773 A1 CA2829773 A1 CA 2829773A1 CA 2829773 A CA2829773 A CA 2829773A CA 2829773 A CA2829773 A CA 2829773A CA 2829773 A1 CA2829773 A1 CA 2829773A1
- Authority
- CA
- Canada
- Prior art keywords
- syringe
- component
- assembly
- housing
- force
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 329
- 238000002347 injection Methods 0.000 title claims abstract description 248
- 239000007924 injection Substances 0.000 title claims abstract description 248
- 238000000429 assembly Methods 0.000 title description 8
- 238000003780 insertion Methods 0.000 claims description 494
- 230000037431 insertion Effects 0.000 claims description 494
- 238000010304 firing Methods 0.000 claims description 215
- 230000007246 mechanism Effects 0.000 claims description 209
- 238000000418 atomic force spectrum Methods 0.000 claims description 186
- 238000001514 detection method Methods 0.000 claims description 49
- 238000012360 testing method Methods 0.000 claims description 35
- 230000008878 coupling Effects 0.000 claims description 34
- 238000010168 coupling process Methods 0.000 claims description 34
- 238000005859 coupling reaction Methods 0.000 claims description 34
- 230000004044 response Effects 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 13
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 230000036961 partial effect Effects 0.000 claims description 7
- 230000008569 process Effects 0.000 abstract description 238
- 238000013459 approach Methods 0.000 description 48
- 239000000126 substance Substances 0.000 description 33
- 238000004873 anchoring Methods 0.000 description 27
- 230000001133 acceleration Effects 0.000 description 26
- 108700012920 TNF Proteins 0.000 description 25
- 229910000831 Steel Inorganic materials 0.000 description 22
- 239000010959 steel Substances 0.000 description 22
- 230000006835 compression Effects 0.000 description 20
- 238000007906 compression Methods 0.000 description 20
- 238000004891 communication Methods 0.000 description 17
- 230000007423 decrease Effects 0.000 description 15
- 239000003112 inhibitor Substances 0.000 description 13
- 229960002964 adalimumab Drugs 0.000 description 11
- 239000007788 liquid Substances 0.000 description 10
- 230000008093 supporting effect Effects 0.000 description 10
- 230000004913 activation Effects 0.000 description 9
- 238000003825 pressing Methods 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 238000010586 diagram Methods 0.000 description 8
- 230000008713 feedback mechanism Effects 0.000 description 8
- 229960000598 infliximab Drugs 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000000007 visual effect Effects 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000001960 triggered effect Effects 0.000 description 6
- 108010081589 Becaplermin Proteins 0.000 description 5
- 108010008165 Etanercept Proteins 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 229940090047 auto-injector Drugs 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000006073 displacement reaction Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- -1 e.g. Proteins 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 229960001743 golimumab Drugs 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000013011 mating Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229940048921 humira Drugs 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000010453 quartz Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010069803 Injury associated with device Diseases 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 102100040990 Platelet-derived growth factor subunit B Human genes 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 229960004787 becaplermin Drugs 0.000 description 3
- HYNPZTKLUNHGPM-KKERQHFVSA-N becaplermin Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]5CCCN5C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]6CCCN6C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]7CCCN7C(=O)[C@H](Cc8c[nH]c9c8cccc9)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)N HYNPZTKLUNHGPM-KKERQHFVSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229960000403 etanercept Drugs 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000012966 insertion method Methods 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 229960005267 tositumomab Drugs 0.000 description 3
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 2
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 2
- 102000015790 Asparaginase Human genes 0.000 description 2
- 108010024976 Asparaginase Proteins 0.000 description 2
- 108010019673 Darbepoetin alfa Proteins 0.000 description 2
- 108010074604 Epoetin Alfa Proteins 0.000 description 2
- 108010029961 Filgrastim Proteins 0.000 description 2
- 101001018026 Homo sapiens Lysosomal alpha-glucosidase Proteins 0.000 description 2
- 108010078049 Interferon alpha-2 Proteins 0.000 description 2
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 2
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 2
- 108010039185 Tenecteplase Proteins 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108010056760 agalsidase beta Proteins 0.000 description 2
- 108700025316 aldesleukin Proteins 0.000 description 2
- 229960003115 certolizumab pegol Drugs 0.000 description 2
- 108010084052 continuous erythropoietin receptor activator Proteins 0.000 description 2
- 108010017271 denileukin diftitox Proteins 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 108010067396 dornase alfa Proteins 0.000 description 2
- 229940073621 enbrel Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108010089296 galsulfase Proteins 0.000 description 2
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 2
- 102000045921 human GAA Human genes 0.000 description 2
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 2
- 108010072166 idursulfase Proteins 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 108010010648 interferon alfacon-1 Proteins 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000006855 networking Effects 0.000 description 2
- 108010046821 oprelvekin Proteins 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 229960001972 panitumumab Drugs 0.000 description 2
- 108010044644 pegfilgrastim Proteins 0.000 description 2
- 108010092853 peginterferon alfa-2a Proteins 0.000 description 2
- 230000037368 penetrate the skin Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 229940107568 pulmozyme Drugs 0.000 description 2
- 108010084837 rasburicase Proteins 0.000 description 2
- 229940116157 regranex Drugs 0.000 description 2
- 229940116176 remicade Drugs 0.000 description 2
- 108010051412 reteplase Proteins 0.000 description 2
- 108010074523 rimabotulinumtoxinB Proteins 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 108010017584 romiplostim Proteins 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960003824 ustekinumab Drugs 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101710117542 Botulinum neurotoxin type A Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 101001081555 Homo sapiens Plasma protease C1 inhibitor Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100029199 Iduronate 2-sulfatase Human genes 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010005716 Interferon beta-1a Proteins 0.000 description 1
- 108010005714 Interferon beta-1b Proteins 0.000 description 1
- 102100030694 Interleukin-11 Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
- XYVNHPYNSPGYLI-UUOKFMHZSA-N [(2r,3s,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H]1O XYVNHPYNSPGYLI-UUOKFMHZSA-N 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 229940099550 actimmune Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940099983 activase Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960003227 afelimomab Drugs 0.000 description 1
- 229960004470 agalsidase beta Drugs 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 229940022705 aldurazyme Drugs 0.000 description 1
- 229960002459 alefacept Drugs 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229960004593 alglucosidase alfa Drugs 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229960003318 alteplase Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940115115 aranesp Drugs 0.000 description 1
- 229940094361 arcalyst Drugs 0.000 description 1
- 229950005725 arcitumomab Drugs 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940021459 betaseron Drugs 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229940089093 botox Drugs 0.000 description 1
- 229940094657 botulinum toxin type a Drugs 0.000 description 1
- 229940009550 c1 esterase inhibitor Drugs 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- 229940034605 capromab pendetide Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 229940090100 cimzia Drugs 0.000 description 1
- 229940088949 cinryze Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 229960005029 darbepoetin alfa Drugs 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229960002923 denileukin diftitox Drugs 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229940056176 drotrecogin alfa Drugs 0.000 description 1
- 108010008250 drotrecogin alfa activated Proteins 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229960002224 eculizumab Drugs 0.000 description 1
- 229960001776 edrecolomab Drugs 0.000 description 1
- 229940012882 elaprase Drugs 0.000 description 1
- KUBARPMUNHKBIQ-VTHUDJRQSA-N eliglustat tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1.C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1 KUBARPMUNHKBIQ-VTHUDJRQSA-N 0.000 description 1
- 229940053603 elitek Drugs 0.000 description 1
- 229940073038 elspar Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229960003388 epoetin alfa Drugs 0.000 description 1
- 229940089118 epogen Drugs 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229940014516 fabrazyme Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 229960005390 galsulfase Drugs 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 102000044507 human SERPING1 Human genes 0.000 description 1
- 229960002396 idursulfase Drugs 0.000 description 1
- 229950007354 imciromab Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229940090438 infergen Drugs 0.000 description 1
- 229960003521 interferon alfa-2a Drugs 0.000 description 1
- 229960003358 interferon alfacon-1 Drugs 0.000 description 1
- 229960004461 interferon beta-1a Drugs 0.000 description 1
- 108010042414 interferon gamma-1b Proteins 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 229940065223 kepivance Drugs 0.000 description 1
- 229940054136 kineret Drugs 0.000 description 1
- 229960002486 laronidase Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960001046 methoxy polyethylene glycol-epoetin beta Drugs 0.000 description 1
- 229940029238 mircera Drugs 0.000 description 1
- 229960003816 muromonab-cd3 Drugs 0.000 description 1
- 229940112646 myobloc Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229940103023 myozyme Drugs 0.000 description 1
- 229940068704 naglazyme Drugs 0.000 description 1
- 229940071846 neulasta Drugs 0.000 description 1
- 229940082926 neumega Drugs 0.000 description 1
- 229940029345 neupogen Drugs 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- 229940100027 ontak Drugs 0.000 description 1
- 229960001840 oprelvekin Drugs 0.000 description 1
- 229940035567 orencia Drugs 0.000 description 1
- 229940029358 orthoclone okt3 Drugs 0.000 description 1
- 229960002404 palifermin Drugs 0.000 description 1
- 229960000402 palivizumab Drugs 0.000 description 1
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 1
- 229940002988 pegasys Drugs 0.000 description 1
- 229960001373 pegfilgrastim Drugs 0.000 description 1
- 229960003930 peginterferon alfa-2a Drugs 0.000 description 1
- 229940067082 pentetate Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940087463 proleukin Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229960000424 rasburicase Drugs 0.000 description 1
- 229940038850 rebif Drugs 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 229940107685 reopro Drugs 0.000 description 1
- 239000012858 resilient material Substances 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229940116243 retavase Drugs 0.000 description 1
- 229960002917 reteplase Drugs 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 108010046141 rilonacept Proteins 0.000 description 1
- 229960001886 rilonacept Drugs 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229960004262 romiplostim Drugs 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229940115586 simulect Drugs 0.000 description 1
- 229940055944 soliris Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940036185 synagis Drugs 0.000 description 1
- 229960000216 tenecteplase Drugs 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 229940113038 tnkase Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012780 transparent material Substances 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 229940099073 xolair Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M5/2033—Spring-loaded one-shot injectors with or without automatic needle insertion
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B23—MACHINE TOOLS; METAL-WORKING NOT OTHERWISE PROVIDED FOR
- B23P—METAL-WORKING NOT OTHERWISE PROVIDED FOR; COMBINED OPERATIONS; UNIVERSAL MACHINE TOOLS
- B23P19/00—Machines for simply fitting together or separating metal parts or objects, or metal and non-metal parts, whether or not involving some deformation; Tools or devices therefor so far as not provided for in other classes
- B23P19/04—Machines for simply fitting together or separating metal parts or objects, or metal and non-metal parts, whether or not involving some deformation; Tools or devices therefor so far as not provided for in other classes for assembling or disassembling parts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M2005/206—With automatic needle insertion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2207/00—Methods of manufacture, assembly or production
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2207/00—Methods of manufacture, assembly or production
- A61M2207/10—Device therefor
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T29/00—Metal working
- Y10T29/49—Method of mechanical manufacture
- Y10T29/49764—Method of mechanical manufacture with testing or indicating
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T29/00—Metal working
- Y10T29/53—Means to assemble or disassemble
- Y10T29/53022—Means to assemble or disassemble with means to test work or product
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Mechanical Engineering (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Automatic Assembly (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161454097P | 2011-03-18 | 2011-03-18 | |
| US61/454,097 | 2011-03-18 | ||
| PCT/US2012/029682 WO2012129174A1 (en) | 2011-03-18 | 2012-03-19 | Systems. devices and methods for assembling automatic injection devices and sub-asseblies thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2829773A1 true CA2829773A1 (en) | 2012-09-27 |
Family
ID=45937593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2829773A Abandoned CA2829773A1 (en) | 2011-03-18 | 2012-03-19 | Systems, devices and methods for assembling automatic injection devices and sub-assemblies thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20120233834A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2686036A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2014511711A (cg-RX-API-DMAC7.html) |
| CN (1) | CN103608053B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012231178B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112013023967A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2829773A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2013010699A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012129174A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0414054D0 (en) | 2004-06-23 | 2004-07-28 | Owen Mumford Ltd | Improvements relating to automatic injection devices |
| NZ555256A (en) | 2004-11-22 | 2011-07-29 | Intelliject Inc | Housing, typically similar to credit card size, with compressed gas container, medicament container(s) for user to inject medicament |
| US7648483B2 (en) | 2004-11-22 | 2010-01-19 | Intelliject, Inc. | Devices, systems and methods for medicament delivery |
| US8206360B2 (en) | 2005-02-01 | 2012-06-26 | Intelliject, Inc. | Devices, systems and methods for medicament delivery |
| PL2058020T3 (pl) | 2005-02-01 | 2013-03-29 | Kaleo Inc | Urządzenie do podawania leków |
| US9022980B2 (en) | 2005-02-01 | 2015-05-05 | Kaleo, Inc. | Medical injector simulation device |
| US8361026B2 (en) | 2005-02-01 | 2013-01-29 | Intelliject, Inc. | Apparatus and methods for self-administration of vaccines and other medicaments |
| US8231573B2 (en) | 2005-02-01 | 2012-07-31 | Intelliject, Inc. | Medicament delivery device having an electronic circuit system |
| TWI527603B (zh) | 2006-06-30 | 2016-04-01 | 艾伯維生物技術有限責任公司 | 自動注射裝置 |
| US8021344B2 (en) | 2008-07-28 | 2011-09-20 | Intelliject, Inc. | Medicament delivery device configured to produce an audible output |
| USD994111S1 (en) | 2008-05-12 | 2023-08-01 | Kaleo, Inc. | Medicament delivery device cover |
| BRPI1012162A2 (pt) | 2009-04-29 | 2016-01-12 | Abbott Biotech Ltd | dispositivo de injeção automática |
| WO2011075524A1 (en) | 2009-12-15 | 2011-06-23 | Abbott Biotechnology Ltd | Improved firing button for automatic injection device |
| RU2695703C2 (ru) | 2010-04-21 | 2019-07-25 | Эббви Байотекнолоджи Лтд. | Носимое устройство для автоматической инъекции для управляемой подачи терапевтических агентов |
| CA2825316C (en) | 2011-01-24 | 2020-05-05 | Abbvie Biotechnology Ltd. | Automatic injection devices having overmolded gripping surfaces |
| KR102001050B1 (ko) | 2011-01-24 | 2019-07-17 | 엘캠 메디컬 애그리컬처럴 코오퍼레이티브 어소시에이션 리미티드 | 인젝터 |
| US8708968B2 (en) | 2011-01-24 | 2014-04-29 | Abbvie Biotechnology Ltd. | Removal of needle shields from syringes and automatic injection devices |
| US9084849B2 (en) | 2011-01-26 | 2015-07-21 | Kaleo, Inc. | Medicament delivery devices for administration of a medicament within a prefilled syringe |
| US8627816B2 (en) | 2011-02-28 | 2014-01-14 | Intelliject, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
| US8939943B2 (en) | 2011-01-26 | 2015-01-27 | Kaleo, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
| WO2014037946A1 (en) * | 2012-09-05 | 2014-03-13 | Elcam Medical Agricultural Cooperative Association Ltd. | Electronic auto-injection device |
| EP2911717B1 (en) * | 2012-10-23 | 2019-05-22 | Insuline Medical Ltd. | Drug dispensing-tracking device, system and method |
| CN103994845B (zh) * | 2013-02-19 | 2019-09-10 | 精工爱普生株式会社 | 力检测装置、机械手、以及移动体 |
| US20140260694A1 (en) * | 2013-03-15 | 2014-09-18 | Chevron U.S.A. Inc. | Automated Tracer Sampling and Measurement System |
| WO2015024960A1 (en) * | 2013-08-22 | 2015-02-26 | Sanofi-Aventis Deutschland Gmbh | Control unit for a drug delivery device |
| FR3014969B1 (fr) * | 2013-12-16 | 2016-01-29 | Lisi Aerospace | Fixation temporaire |
| CA2937327C (en) * | 2014-01-21 | 2018-02-27 | Parenteral Technologies, Llc | Force actuated injection device |
| US10625026B2 (en) | 2014-01-21 | 2020-04-21 | Parenteral Technologies, Llc | Force actuated injection device |
| US9517307B2 (en) | 2014-07-18 | 2016-12-13 | Kaleo, Inc. | Devices and methods for delivering opioid antagonists including formulations for naloxone |
| WO2016020358A2 (en) * | 2014-08-08 | 2016-02-11 | Sanofi-Aventis Deutschland Gmbh | Method, arrangement and drug delivery device for testing the mechanical integrity of a cartridge arranged inside the device |
| KR20170097020A (ko) | 2014-12-23 | 2017-08-25 | 오토메드 피티와이 리미티드 | 딜리버리 장치, 시스템 및 관련 방법 |
| CN107530502B (zh) | 2015-02-20 | 2021-01-15 | 里珍纳龙药品有限公司 | 注射器系统、活塞密封系统、塞子系统 |
| US10576206B2 (en) | 2015-06-30 | 2020-03-03 | Kaleo, Inc. | Auto-injectors for administration of a medicament within a prefilled syringe |
| EP3834865B1 (en) * | 2015-08-27 | 2025-04-30 | E3D Agricultural Cooperative Association Ltd. | Reusable automatic injection device |
| WO2017087888A1 (en) | 2015-11-18 | 2017-05-26 | President And Fellows Of Harvard College | Systems and methods for monitoring, managing, and treating asthma and anaphylaxis |
| CN106236319B (zh) * | 2016-09-29 | 2017-12-29 | 深圳市智屏微科技有限公司 | 一种注射器的注射端结构以及注射器 |
| CA3046228A1 (en) | 2016-12-23 | 2018-06-28 | Kaleo, Inc. | Medicament delivery device and methods for delivering drugs to infants and children |
| WO2019012475A2 (en) | 2017-07-12 | 2019-01-17 | Insuline Medical Ltd. | DRUG MONITORING DEVICE |
| GB201718315D0 (en) * | 2017-11-06 | 2017-12-20 | Owen Mumford Ltd | Auto-injector |
| CN111511427B (zh) * | 2017-12-28 | 2023-01-06 | 赛诺菲 | 用于附接到注射装置的传感器装置 |
| CN112165963B (zh) | 2018-05-24 | 2023-06-06 | 诺华股份有限公司 | 药物自动输送装置 |
| US12478739B2 (en) | 2018-12-29 | 2025-11-25 | Kaleo, Inc. | Devices and methods for delivery of substances within a prefilled syringe |
| EP4009936A4 (en) | 2019-08-09 | 2023-08-09 | Kaleo, Inc. | DEVICES AND METHODS FOR DELIVERING SUBSTANCES IN A PRE-FILLED SYRINGE |
| US11829795B2 (en) * | 2019-12-30 | 2023-11-28 | UiPath, Inc. | Trigger service management for robotic process automation (RPA) |
| WO2021204761A1 (en) * | 2020-04-06 | 2021-10-14 | Phillips-Medisize A/S | Method for assembling a cassette for use in an auto injector |
| US11957542B2 (en) | 2020-04-30 | 2024-04-16 | Automed Patent Holdco, Llc | Sensing complete injection for animal injection device |
| US11850402B2 (en) | 2020-07-09 | 2023-12-26 | Eli Lilly And Company | Automatic injection device with reusable portion |
| US12268847B1 (en) | 2021-02-10 | 2025-04-08 | Kaleo, Inc. | Devices and methods for delivery of substances within a medicament container |
| US20250186697A1 (en) * | 2022-03-11 | 2025-06-12 | Sanofi | Workpiece carrier for an injection device |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3541663A (en) * | 1968-08-21 | 1970-11-24 | Roman Szpur | Syringe needle attachment device |
| US3910260A (en) | 1972-03-01 | 1975-10-07 | Survival Technology | Method and apparatus of treating heart attack patients prior to the establishment of qualified direct contact personal care |
| US4004577A (en) | 1972-12-04 | 1977-01-25 | Survival Technology, Inc. | Method of treating heart attack patients prior to the establishment of qualified direct contact personal care |
| US3941130A (en) | 1975-03-18 | 1976-03-02 | Tibbs Robert C | Sequential trigger release for injection device |
| US4261358A (en) | 1979-10-01 | 1981-04-14 | Walter Vargas | Automatic syringe plunger |
| US4795433A (en) | 1985-05-20 | 1989-01-03 | Survival Technology, Inc. | Automatic injector for emergency treatment |
| US4689042A (en) | 1985-05-20 | 1987-08-25 | Survival Technology, Inc. | Automatic medicament ingredient mixing and injecting apparatus |
| US4855923A (en) * | 1988-01-06 | 1989-08-08 | Xerox Corporation | Parts assembly using signature analysis |
| US5142769A (en) * | 1988-07-14 | 1992-09-01 | Coors Brewing Company | Monitor and control assembly for use with a can end press |
| US5085642A (en) | 1989-07-17 | 1992-02-04 | Survival Technology, Inc. | Conveniently carried frequent use autoinjector |
| US5102393A (en) | 1989-07-17 | 1992-04-07 | Survival Technology, Inc. | Autoinjector converted from intramuscular to subcutaneous mode of injection |
| US6498237B2 (en) | 1989-08-07 | 2002-12-24 | Peptech Limited | Tumor necrosis factor antibodies |
| US5959087A (en) | 1989-08-07 | 1999-09-28 | Peptide Technology, Ltd. | Tumour necrosis factor binding ligands |
| CA2065346C (en) | 1989-09-05 | 2005-03-29 | Craig A. Smith | Tumor necrosis factor-.alpha. and-.beta. receptors |
| US5092843A (en) | 1990-04-12 | 1992-03-03 | Survival Technology, Inc. | Dispersion multichamber auto-injector |
| IT1246154B (it) * | 1990-07-13 | 1994-11-15 | Italtractor | Metodo per accoppiare gli elementi di una articolazione con gioco di funzionamento prestabilito mediante l'esecuzione di collegamenti forzati |
| US5656272A (en) | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
| US5267963A (en) | 1992-08-21 | 1993-12-07 | Nicholas Bachynsky | Medication injection device |
| NZ256293A (en) | 1992-09-15 | 1997-06-24 | Immunex Corp | Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| WO1997029131A1 (en) | 1996-02-09 | 1997-08-14 | Basf Aktiengesellschaft | HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a) |
| DE19705462C2 (de) * | 1997-02-13 | 2002-01-10 | Schmidt Feinmech | Verfahren zum Betreiben einer Elektropresse |
| GB9716065D0 (en) * | 1997-07-31 | 1997-10-01 | Owen Mumford Ltd | Improvements relating to injection devices |
| US6149626A (en) | 1997-10-03 | 2000-11-21 | Bachynsky; Nicholas | Automatic injecting syringe apparatus |
| SE9803662D0 (sv) | 1998-10-26 | 1998-10-26 | Pharmacia & Upjohn Ab | Autoinjector |
| UA81743C2 (uk) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
| JP3978785B2 (ja) * | 2003-09-10 | 2007-09-19 | ニプロ株式会社 | 外れ防止機構を備えたプランジャー |
| JP4990760B2 (ja) * | 2004-05-28 | 2012-08-01 | シラグ・ゲーエムベーハー・インターナショナル | 注入装置 |
| TWI527603B (zh) * | 2006-06-30 | 2016-04-01 | 艾伯維生物技術有限責任公司 | 自動注射裝置 |
| EP2099584B1 (de) * | 2006-07-18 | 2017-10-25 | Kistler Holding AG | Fügeeinheit |
| IL177036A (en) * | 2006-07-23 | 2011-05-31 | Sagiv Agudah Shitufit Chaklait Be Am | Device and method for connecting a pipe fitting to a pipe |
| DE102006049528A1 (de) * | 2006-09-28 | 2008-04-03 | Robert Bosch Gmbh | Vorrichtung und Verfahren zur Montage eines Nadelschutzes auf einen Spritzenkörper |
| JP2010279692A (ja) * | 2009-05-26 | 2010-12-16 | Mg2 Srl | 注射器のピストンを捩じ込むための方法及び装置 |
-
2012
- 2012-03-19 CN CN201280023943.5A patent/CN103608053B/zh not_active Expired - Fee Related
- 2012-03-19 US US13/424,194 patent/US20120233834A1/en not_active Abandoned
- 2012-03-19 WO PCT/US2012/029682 patent/WO2012129174A1/en not_active Ceased
- 2012-03-19 JP JP2013558239A patent/JP2014511711A/ja not_active Ceased
- 2012-03-19 BR BR112013023967A patent/BR112013023967A2/pt not_active Application Discontinuation
- 2012-03-19 EP EP12713470.8A patent/EP2686036A1/en not_active Withdrawn
- 2012-03-19 CA CA2829773A patent/CA2829773A1/en not_active Abandoned
- 2012-03-19 MX MX2013010699A patent/MX2013010699A/es unknown
- 2012-03-19 AU AU2012231178A patent/AU2012231178B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012231178A1 (en) | 2013-05-02 |
| MX2013010699A (es) | 2014-03-27 |
| AU2012231178B2 (en) | 2015-11-05 |
| BR112013023967A2 (pt) | 2016-01-19 |
| WO2012129174A1 (en) | 2012-09-27 |
| WO2012129174A8 (en) | 2013-03-14 |
| US20120233834A1 (en) | 2012-09-20 |
| EP2686036A1 (en) | 2014-01-22 |
| JP2014511711A (ja) | 2014-05-19 |
| CN103608053A (zh) | 2014-02-26 |
| CN103608053B (zh) | 2016-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012231178B2 (en) | Systems, devices and methods for assembling automatic injection devices and sub-assemblies thereof | |
| US9956353B2 (en) | Shroud deployment in automatic injection devices | |
| AU2014210677B2 (en) | Improved firing button for automatic injection device | |
| US9561328B2 (en) | Automatic injection device | |
| AU2013204406B2 (en) | Automatic injection device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170320 |
|
| FZDE | Discontinued |
Effective date: 20181005 |